Copyright ©The Author(s) 2021.
World J Gastrointest Oncol. Jul 15, 2021; 13(7): 673-683
Published online Jul 15, 2021. doi: 10.4251/wjgo.v13.i7.673
Table 1 Clinical trials of hepatocellular carcinoma neoantigen vaccines
Number enrolled
NCT number
Initial date
Hepatocellular carcinomaNeoantigen DNA vaccine (GNOS-PV02), plasmid encoded IL-12 (INO-9012), pembrolizumab (MK-3475)Ⅰ/Ⅱ24NCT04251117January 31, 2020Geneos Therapeutics
Fibrolamellar hepatocellular carcinomaDNAJB1-PRKACA peptide vaccine, nivolumab, ipilimumab12NCT04248569January 30, 2020Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb, Fibrolamellar Cancer Foundation
Gastric cancer, hepatocellular carcinoma, non-small-cell lung cancer, colorectal cancerNeoantigen-primed DC vaccine80NCT04147078October 31, 2019Sichuan University
Hepatocellular carcinomaNeoantigen-based DC vaccine, microwave ablation24NCT03674073September 17, 2018Chinese PLA General Hospital, Likang Life Sciences Holdings Limited
Hepatocellular carcinomaNRT radiotherapyⅠ/Ⅱ40NCT03199807June 27, 2017The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School